MorphoSys AG (MORG.DE)
84.35EUR
19 Apr 2018
€-2.15 (-2.49%)
€86.50
€85.50
€85.85
€84.00
17,201
130,949
€88.40
€50.50
About
Overall
| Beta: | 0.78 |
| Market Cap(Mil.): | €2,171.58 |
| Shares Outstanding(Mil.): | 29.35 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MORG.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -2.61 | -- | -- |
| ROI: | -19.28 | 1.58 | 14.38 |
| ROE: | -19.78 | 2.41 | 16.07 |
BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq
* MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ
BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS
* DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES
BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing
* MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING
BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan
* SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN Source text for Eikon: Further company coverage:
BRIEF-Morphosys AG Files For U.S. IPO Of Up To $150 Mln
* MORPHOSYS AG FILES FOR U.S. IPO OF UP TO $150 MILLION – SEC FILING
BRIEF-Morphosys AG Says Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) Offering
* SAYS FILES REGISTRATION STATEMENT IN UNITED STATES FOR A PROPOSED AMERICAN DEPOSITARY SHARES (ADS) OFFERING
BRIEF-Morphosys Sees EBIT Loss Widening To 110-120 Mln Euros In 2018
* REVENUES 2017 UP 34% TO EUR 66.8 MILLION (GUIDANCE EUR 63 TO 66 MILLION)
BRIEF-Morphosys Announces New Data On Tremfya
* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT TREMFYA(R) (GUSELKUMAB) DATA DEMONSTRATED LONG-TERM SKIN CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text for Eikon: Further company coverage:
BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106
* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT
BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis
* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS
Estimates